Skip to Main Content

TrialNet TOPPLE Study for People with Type 1 Diabetes

Conditions

Diabetes Mellitus - Type 1

Phase I

What is the purpose of this trial?

TrialNet is testing the safety of a new treatment, NNC0361-0041, in adults, 18-45, with Type 1 Diabetes (T1D) diagnosed within the past 48 months. The treatment is a plasmid vector designed to transfer DNA into cells, where it can communicate with the immune system. Earlier studies in the lab show this treatment might retrain the immune system to stop its attack on insulin-producing beta cells.

While plasmids are small circular pieces of DNA, they do not change your DNA. They are currently being studied in many clinical trials for other conditions.

This study has a 12-week treatment phase, followed by 9 months of follow up.

  • Trial with
    National Institute of Diabetes and Digestive & Kidney Diseases (NIDDK)
  • Start Date
    11/17/2020
  • End Date
    12/26/2021

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/27/2021
  • Study HIC
    #2000029217